Exact Sciences
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.
Exact Sciences Blood-Based Colon Cancer Screening Data at ESMO Exceeds Expectations
Although the results were better than expected, the company cautioned that it expects lower performance in its prospective trial readout, planned for early next year.
GenomeWeb Top 40 Rises Less Than 1 Percent in August, In Line With Broader Market
The Dow Jones Industrial Average rose 2 percent, while the Nasdaq and Nasdaq Biotech Index both rose less than 1 percent.
Exact Sciences Enrolls First Patient in Multi-Cancer Early Detection Study
Participants enrolled in the registry study will receive three years of MCED testing and two years of follow-on data collection.
Exact Sciences Reports 12 Percent Q2 Revenue Jump, Breaks Quarterly Test Volume Record
The company said it screened more that 1 million people for colorectal cancer during the quarter, and also tested a record number with its Oncotype DX breast cancer test.